Global Information
회사소개 | 문의 | 비교리스트

세계의 알츠하이머병 치료 및 진단 시장 예측(2022-2030년)

Global Alzheimer´s Disease Therapeutics & Diagnostics Market Forecast 2022-2030

리서치사 Inkwood Research
발행일 2022년 06월 상품코드 1091864
페이지 정보 영문 235 Pages 배송안내 2-3일 (영업일 기준)
가격
US $ 2,500 ₩ 3,292,000 PDF (Single User License) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 되지 않으며, 인쇄 또한 불가능합니다.
US $ 3,000 ₩ 3,951,000 PDF (Multi User License) help
동일 사업장(소재지) 내 5명까지 이용가능한 라이센스입니다. 인쇄는 1명당 1회에 한해 가능하며 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 4,500 ₩ 5,926,000 PDF (Enterprisewide License) help
동일 기업 및 100% 자회사의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수 제한은 없습니다. PDF 파일은 Copy & Paste 가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.

주의 : 라이선스에 따라 자료 이용 및 인쇄 등에 제약이 있을 수 있습니다. 자세한 내용은 라이선스 설명문( )을 참고하여 주시기 바랍니다.



세계의 알츠하이머병 치료 및 진단 시장 예측(2022-2030년) Global Alzheimer´s Disease Therapeutics & Diagnostics Market Forecast 2022-2030
발행일 : 2022년 06월 페이지 정보 : 영문 235 Pages

본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

세계의 알츠하이머병 치료 및 진단 시장 규모는 2022-2030년 예측기간 중 6.61%의 CAGR로 확대될 것으로 예측됩니다. 알츠하이머병 만연, 신규 진단 기술 출현, 파이프라인 약제 증가에 의해 시장 성장이 촉진되고 있습니다.

세계의 알츠하이머병 치료 및 진단(Alzheimer's Disease Therapeutics & Diagnostics) 시장에 대해 조사했으며, 시장 개요와 함께 COVID-19의 영향, 지역별 동향, 경쟁 상황 및 시장에 참여하는 기업 개요 등을 제공합니다.

목차

제1장 조사 범위와 조사 방법

제2장 주요 요약

제3장 시장 역학

  • 상부 시장 분석
  • 주요 성장 촉진요인
    • 고령자 인구 증가
    • 알츠하이머병 만연율 상승
    • 새로운 새로운 진단 기술
    • 파이프라인 의약품 증가
  • 주요 성장 억제요인
    • 후기약 실패
    • 엄격한 정부 규제
    • 대리 마커의 가용성 결여

제4장 주요 분석

  • 알츠하이머병 치료 및 진단 시장 타임라인
  • 알츠하이머병 병기와 중도
  • 알츠하이머병 치료 및 진단 시장에 대한 COVID-19의 영향
  • 동향
  • Porter's Five Forces 분석
  • 주요 구입 기준
  • 공급망 분석
  • 시장 기회 매트릭스
  • 벤더 상황

제5장 치료 및 진단별 시장

  • 치료
  • 진단

제6장 지역 분석

  • 북미
  • 유럽
  • 아시아태평양
  • 기타 지역

제7장 경쟁 상황

  • 주요 전략적 개발
  • 기업 개요
    • ALLERGAN PLC
    • AMARANTUS BIOSCIENCE HOLDINGS INC
    • BAXTER INTERNATIONAL INC
    • BIOGEN INC
    • COGNOPTIX INC
    • EISAI CO LTD
    • ELI LILLY & COMPANY
    • F HOFFMANN-LA ROCHE
    • GE HEALTHCARE
    • JOHNSON & JOHNSON
    • LUPIN LIMITED
    • MERCK & CO INC
    • NOVARTIS AG
    • PFIZER INC
    • SIEMENS HEALTHINEERS AG
    • SUN PHARMACEUTICALS INDUSTRIES LTD
    • TEVA PHARMACEUTICAL INDUSTRIES LIMITED
    • ZYDUS CADILA
KSM 22.07.01

LIST OF TABLES

  • TABLE 1: MARKET SNAPSHOT - ALZHEIMER'S DISEASE THERAPEUTICS & DIAGNOSTICS
  • TABLE 2: GLOBAL ALZHEIMER'S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, BY THERAPEUTICS & DIAGNOSTICS, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
  • TABLE 3: GLOBAL ALZHEIMER'S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, BY THERAPEUTICS & DIAGNOSTICS, FORECAST YEARS, 2022-2030 (IN $ MILLION)
  • TABLE 4: GLOBAL THERAPEUTICS MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
  • TABLE 5: GLOBAL THERAPEUTICS MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)
  • TABLE 6: GLOBAL ALZHEIMER'S DISEASE THERAPEUTICS MARKET, BY DRUGS, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
  • TABLE 7: GLOBAL ALZHEIMER'S DISEASE THERAPEUTICS MARKET, BY DRUGS, FORECAST YEARS, 2022-2030 (IN $ MILLION)
  • TABLE 8: GLOBAL MARKETED DRUGS MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
  • TABLE 9: GLOBAL MARKETED DRUGS MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)
  • TABLE 10: GLOBAL PIPELINE DRUGS MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
  • TABLE 11: GLOBAL PIPELINE DRUGS MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)
  • TABLE 12: GLOBAL ALZHEIMER'S DISEASE THERAPEUTICS MARKET, BY DISEASE STAGE, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
  • TABLE 13: GLOBAL ALZHEIMER'S DISEASE THERAPEUTICS MARKET, BY DISEASE STAGE, FORECAST YEARS, 2022-2030 (IN $ MILLION)
  • TABLE 14: GLOBAL LATE-STAGE: SEVERE AD MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
  • TABLE 15: GLOBAL LATE-STAGE: SEVERE AD MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)
  • TABLE 16: GLOBAL EARLY/MIDDLE STAGE: MILD TO MODERATE AD MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
  • TABLE 17: GLOBAL EARLY/MIDDLE STAGE: MILD TO MODERATE AD MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)
  • TABLE 18: GLOBAL PRODROMAL STAGE MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
  • TABLE 19: GLOBAL PRODROMAL STAGE MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)
  • TABLE 20: GLOBAL ALZHEIMER'S DISEASE THERAPEUTICS MARKET, BY GENERIC & BRANDED, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
  • TABLE 21: GLOBAL ALZHEIMER'S DISEASE THERAPEUTICS MARKET, BY GENERIC & BRANDED, FORECAST YEARS, 2022-2030 (IN $ MILLION)
  • TABLE 22: GLOBAL BRANDED MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
  • TABLE 23: GLOBAL BRANDED MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)
  • TABLE 24: GLOBAL GENERIC MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
  • TABLE 25: GLOBAL GENERIC MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)
  • TABLE 26: GLOBAL DIAGNOSTICS MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
  • TABLE 27: GLOBAL DIAGNOSTICS MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)
  • TABLE 28: GLOBAL ALZHEIMER'S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, BY DIAGNOSTICS, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
  • TABLE 29: GLOBAL ALZHEIMER'S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, BY DIAGNOSTICS, FORECAST YEARS, 2022-2030 (IN $ MILLION)
  • TABLE 30: GLOBAL LUMBAR PUNCTURE TEST MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
  • TABLE 31: GLOBAL LUMBAR PUNCTURE TEST MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)
  • TABLE 32: GLOBAL POSITRON EMISSION TOMOGRAPHY MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
  • TABLE 33: GLOBAL POSITRON EMISSION TOMOGRAPHY MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)
  • TABLE 34: GLOBAL ELECTROENCEPHALOGRAPHY MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
  • TABLE 35: GLOBAL ELECTROENCEPHALOGRAPHY MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)
  • TABLE 36: GLOBAL MAGNETIC RESONANCE IMAGING MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
  • TABLE 37: GLOBAL MAGNETIC RESONANCE IMAGING MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)
  • TABLE 38: GLOBAL COMPUTED TOMOGRAPHY MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
  • TABLE 39: GLOBAL COMPUTED TOMOGRAPHY MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)
  • TABLE 40: GLOBAL BLOOD TEST MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
  • TABLE 41: GLOBAL BLOOD TEST MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)
  • TABLE 42: GLOBAL OTHER DIAGNOSTICS MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
  • TABLE 43: GLOBAL OTHER DIAGNOSTICS MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)
  • TABLE 44: GLOBAL ALZHEIMER'S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, BY GEOGRAPHY, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
  • TABLE 45: GLOBAL ALZHEIMER'S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, BY GEOGRAPHY, FORECAST YEARS, 2022-2030 (IN $ MILLION)
  • TABLE 46: NORTH AMERICA ALZHEIMER'S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, BY COUNTRY, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
  • TABLE 47: NORTH AMERICA ALZHEIMER'S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, BY COUNTRY, FORECAST YEARS, 2022-2030 (IN $ MILLION)
  • TABLE 48: LEADING PLAYERS OPERATING IN NORTH AMERICA ALZHEIMER'S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET
  • TABLE 49: EUROPE ALZHEIMER'S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, BY COUNTRY, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
  • TABLE 50: EUROPE ALZHEIMER'S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, BY COUNTRY, FORECAST YEARS, 2022-2030 (IN $ MILLION)
  • TABLE 51: LEADING PLAYERS OPERATING IN EUROPE ALZHEIMER'S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET
  • TABLE 52: ASIA-PACIFIC ALZHEIMER'S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, BY COUNTRY, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
  • TABLE 53: ASIA-PACIFIC ALZHEIMER'S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, BY COUNTRY, FORECAST YEARS, 2022-2030 (IN $ MILLION)
  • TABLE 54: LEADING PLAYERS OPERATING IN ASIA-PACIFIC ALZHEIMER'S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET
  • TABLE 55: REST OF WORLD ALZHEIMER'S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
  • TABLE 56: REST OF WORLD ALZHEIMER'S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)
  • TABLE 57: LEADING PLAYERS OPERATING IN REST OF WORLD ALZHEIMER'S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET
  • TABLE 58: LIST OF MERGERS & ACQUISITIONS
  • TABLE 59: LIST OF PRODUCT LAUNCHES & DEVELOPMENTS
  • TABLE 60: LIST OF PARTNERSHIPS & AGREEMENTS
  • TABLE 61: LIST OF BUSINESS EXPANSIONS, ANNOUNCEMENTS, & DIVESTITURES

LIST OF FIGURES

  • FIGURE 1: PIPELINE DRUGS RELATED TO ALZHEIMER'S DISEASE
  • FIGURE 2: KEY MARKET TRENDS
  • FIGURE 3: PORTER'S FIVE FORCES ANALYSIS
  • FIGURE 4: KEY BUYING CRITERIA
  • FIGURE 5: SUPPLY CHAIN ANALYSIS
  • FIGURE 6: OPPORTUNITY MATRIX
  • FIGURE 7: VENDOR LANDSCAPE
  • FIGURE 8: GLOBAL ALZHEIMER'S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, GROWTH POTENTIAL, BY THERAPEUTICS & DIAGNOSTICS, IN 2021
  • FIGURE 9: GLOBAL ALZHEIMER'S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, BY THERAPEUTICS, 2022-2030 (IN $ MILLION)
  • FIGURE 10: GLOBAL ALZHEIMER'S DISEASE THERAPEUTICS MARKET, GROWTH POTENTIAL, BY DRUGS, IN 2021
  • FIGURE 11: GLOBAL ALZHEIMER'S DISEASE THERAPEUTICS MARKET, BY MARKETED DRUGS, 2022-2030 (IN $ MILLION)
  • FIGURE 12: GLOBAL ALZHEIMER'S DISEASE THERAPEUTICS MARKET, BY PIPELINE DRUGS, 2022-2030 (IN $ MILLION)
  • FIGURE 13: GLOBAL ALZHEIMER'S DISEASE THERAPEUTICS MARKET, GROWTH POTENTIAL, BY DISEASE STAGE, IN 2021
  • FIGURE 14: GLOBAL ALZHEIMER'S DISEASE THERAPEUTICS MARKET, BY LATE-STAGE: SEVERE AD, 2022-2030 (IN $ MILLION)
  • FIGURE 15: GLOBAL ALZHEIMER'S DISEASE THERAPEUTICS MARKET, BY EARLY/MIDDLE STAGE: MILD TO MODERATE AD, 2022-2030 (IN $ MILLION)
  • FIGURE 16: GLOBAL ALZHEIMER'S DISEASE THERAPEUTICS MARKET, BY PRODROMAL STAGE, 2022-2030 (IN $ MILLION)
  • FIGURE 17: GLOBAL ALZHEIMER'S DISEASE THERAPEUTICS MARKET, GROWTH POTENTIAL, BY GENERIC & BRANDED, IN 2021
  • FIGURE 18: GLOBAL ALZHEIMER'S DISEASE THERAPEUTICS MARKET, BY BRANDED, 2022-2030 (IN $ MILLION)
  • FIGURE 19: GLOBAL ALZHEIMER'S DISEASE THERAPEUTICS MARKET, BY GENERIC, 2022-2030 (IN $ MILLION)
  • FIGURE 20: GLOBAL ALZHEIMER'S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, BY DIAGNOSTICS, 2022-2030 (IN $ MILLION)
  • FIGURE 21: GLOBAL ALZHEIMER'S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, GROWTH POTENTIAL, BY DIAGNOSTICS, IN 2021
  • FIGURE 22: GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS MARKET, BY LUMBAR PUNCTURE TEST, 2022-2030 (IN $ MILLION)
  • FIGURE 23: GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS MARKET, BY POSITRON EMISSION TOMOGRAPHY, 2022-2030 (IN $ MILLION)
  • FIGURE 24: GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS MARKET, BY ELECTROENCEPHALOGRAPHY, 2022-2030 (IN $ MILLION)
  • FIGURE 25: GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS MARKET, BY MAGNETIC RESONANCE IMAGING, 2022-2030 (IN $ MILLION)
  • FIGURE 26: GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS MARKET, BY COMPUTED TOMOGRAPHY, 2022-2030 (IN $ MILLION)
  • FIGURE 27: GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS MARKET, BY BLOOD TEST, 2022-2030 (IN $ MILLION)
  • FIGURE 28: GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS MARKET, BY OTHER DIAGNOSTICS, 2022-2030 (IN $ MILLION)
  • FIGURE 29: NORTH AMERICA ALZHEIMER'S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, COUNTRY OUTLOOK, 2021 & 2030 (IN %)
  • FIGURE 30: UNITED STATES ALZHEIMER'S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, 2022-2030 (IN $ MILLION)
  • FIGURE 31: CANADA ALZHEIMER'S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, 2022-2030 (IN $ MILLION)
  • FIGURE 32: EUROPE ALZHEIMER'S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, COUNTRY OUTLOOK, 2021 & 2030 (IN %)
  • FIGURE 33: UNITED KINGDOM ALZHEIMER'S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, 2022-2030 (IN $ MILLION)
  • FIGURE 34: GERMANY ALZHEIMER'S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, 2022-2030 (IN $ MILLION)
  • FIGURE 35: FRANCE ALZHEIMER'S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, 2022-2030 (IN $ MILLION)
  • FIGURE 36: ITALY ALZHEIMER'S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, 2022-2030 (IN $ MILLION)
  • FIGURE 37: BELGIUM ALZHEIMER'S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, 2022-2030 (IN $ MILLION)
  • FIGURE 38: POLAND ALZHEIMER'S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, 2022-2030 (IN $ MILLION)
  • FIGURE 39: REST OF EUROPE ALZHEIMER'S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, 2022-2030 (IN $ MILLION)
  • FIGURE 40: ASIA-PACIFIC ALZHEIMER'S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, COUNTRY OUTLOOK, 2021 & 2030 (IN %)
  • FIGURE 41: CHINA ALZHEIMER'S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, 2022-2030 (IN $ MILLION)
  • FIGURE 42: JAPAN ALZHEIMER'S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, 2022-2030 (IN $ MILLION)
  • FIGURE 43: INDIA ALZHEIMER'S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, 2022-2030 (IN $ MILLION)
  • FIGURE 44: SOUTH KOREA ALZHEIMER'S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, 2022-2030 (IN $ MILLION)
  • FIGURE 45: INDONESIA ALZHEIMER'S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, 2022-2030 (IN $ MILLION)
  • FIGURE 46: THAILAND ALZHEIMER'S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, 2022-2030 (IN $ MILLION)
  • FIGURE 47: VIETNAM ALZHEIMER'S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, 2022-2030 (IN $ MILLION)
  • FIGURE 48: AUSTRALIA & NEW ZEALAND ALZHEIMER'S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, 2022-2030 (IN $ MILLION)
  • FIGURE 49: REST OF ASIA-PACIFIC ALZHEIMER'S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, 2022-2030 (IN $ MILLION)
  • FIGURE 50: REST OF WORLD ALZHEIMER'S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, REGIONAL OUTLOOK, 2021 & 2030 (IN %)
  • FIGURE 51: LATIN AMERICA ALZHEIMER'S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, 2022-2030 (IN $ MILLION)
  • FIGURE 52: MIDDLE EAST & AFRICA ALZHEIMER'S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, 2022-2030 (IN $ MILLION)

KEY FINDINGS

The global Alzheimer's disease therapeutics & diagnostics market is anticipated to grow at a 6.61% CAGR during the estimation period between 2022 to 2030. The market growth is accelerated by the rise in the pervasiveness of Alzheimer's disease, emerging novel diagnostic technologies, and the increasing number of pipeline drugs.

MARKET INSIGHTS

Alzheimer's is a neurodegenerative disease characterized by chronic inflammation and accumulation of beta-amyloid peptides. The elderly usually suffer from Alzheimer's disease, which gradually damages their thinking skills and memory, eventually destroying their ability to perform the simplest daily tasks. Alzheimer's disease is the major reason for dementia among the older population. Therefore, the rising geriatric population is a key driver for the global Alzheimer's disease therapeutics and diagnostics market.

Several novel diagnostics technologies have been discovered for Alzheimer's disease (AD), including the invention that identifies mutated proteins in subcellular compartments. This invention describes these mutations that lead to the redistribution of crucial cellular organelles.

Furthermore, alteration of organelles distribution can be a powerful diagnostic tool, an assay to screen novel therapeutic compounds for Alzheimer's disease. This technology's advantage includes identifying mutated proteins, which are directly involved in the genesis of AD. Thus, there is potential for providing a superior AD diagnosis compared to current diagnostic tests.

REGIONAL INSIGHTS

The global Alzheimer's disease therapeutics & diagnostics market assessment entails the analysis of Europe, Asia-Pacific, North America, and Rest of World. The Asia-Pacific region is anticipated to propel with the highest CAGR by 2030, owing to the rapidly increasing geriatric population and government initiative to develop medicines to cure AD.

COMPETITIVE INSIGHTS

The competition in the global market is significantly high owing to the presence of generic medicines. Furthermore, strong competition exists among the key players in developing new diagnostics methodologies and treatments. However, the industry is observing meaningful strategic partnerships to enhance market presence.

Some important global players include: Merck & Co Inc, Cognoptix Inc, Eli Lilly & Company, Johnson & Johnson, etc.

Our report offerings include:

  • Explore key findings of the overall market
  • Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
  • Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
  • Market Segmentation caters to a thorough assessment of key segments with their market estimations
  • Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
  • Key analytics: Porter's Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
  • Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
  • Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments

TABLE OF CONTENTS

1. RESEARCH SCOPE & METHODOLOGY

  • 1.1. STUDY OBJECTIVES
  • 1.2. SCOPE OF STUDY
  • 1.3. METHODOLOGY
  • 1.4. ASSUMPTIONS & LIMITATIONS

2. EXECUTIVE SUMMARY

  • 2.1. MARKET SIZE & ESTIMATES
  • 2.2. MARKET OVERVIEW

3. MARKET DYNAMICS

  • 3.1. PARENT MARKET ANALYSIS
  • 3.2. KEY DRIVERS
    • 3.2.1. GROWING GERIATRIC POPULATION
    • 3.2.2. RISING PERVASIVENESS OF ALZHEIMER'S DISEASE
    • 3.2.3. EMERGING NOVEL DIAGNOSTIC TECHNOLOGIES
    • 3.2.4. INCREASING PIPELINE DRUGS
  • 3.3. KEY RESTRAINTS
    • 3.3.1. FAILURE OF THE LATE-STAGE DRUGS
    • 3.3.2. STRINGENT GOVERNMENT REGULATIONS
    • 3.3.3. LACK OF THE AVAILABILITY OF SURROGATE MARKERS

4. KEY ANALYTICS

  • 4.1. TIMELINE OF ALZHEIMER'S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET
  • 4.2. PHASES AND STERNNESS OF ALZHEIMER'S DISEASE
  • 4.3. IMPACT OF COVID-19 ON ALZHEIMER'S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET
  • 4.4. KEY MARKET TRENDS
  • 4.5. PORTER'S FIVE FORCES ANALYSIS
    • 4.5.1. BUYERS POWER
    • 4.5.2. SUPPLIERS POWER
    • 4.5.3. SUBSTITUTION
    • 4.5.4. NEW ENTRANTS
    • 4.5.5. INDUSTRY RIVALRY
  • 4.6. KEY BUYING CRITERIA
  • 4.7. SUPPLY CHAIN ANALYSIS
  • 4.8. OPPORTUNITY MATRIX
  • 4.9. VENDOR LANDSCAPE

5. MARKET BY THERAPEUTICS & DIAGNOSTICS

  • 5.1. THERAPEUTICS
    • 5.1.1. DRUGS
      • 5.1.1.1. MARKETED DRUGS
      • 5.1.1.2. PIPELINE DRUGS
    • 5.1.2. DISEASE STAGE
      • 5.1.2.1. LATE-STAGE: SEVERE AD
      • 5.1.2.2. EARLY/MIDDLE STAGE: MILD TO MODERATE AD
      • 5.1.2.3. PRODROMAL STAGE
    • 5.1.3. GENERIC & BRANDED
      • 5.1.3.1. BRANDED
      • 5.1.3.2. GENERIC
  • 5.2. DIAGNOSTICS
    • 5.2.1. LUMBAR PUNCTURE TEST
    • 5.2.2. POSITRON EMISSION TOMOGRAPHY
    • 5.2.3. ELECTROENCEPHALOGRAPHY
    • 5.2.4. MAGNETIC RESONANCE IMAGING
    • 5.2.5. COMPUTED TOMOGRAPHY
    • 5.2.6. BLOOD TEST
    • 5.2.7. OTHER DIAGNOSTICS

6. GEOGRAPHICAL ANALYSIS

  • 6.1. NORTH AMERICA
    • 6.1.1. MARKET SIZE & ESTIMATES
    • 6.1.2. KEY GROWTH ENABLERS
    • 6.1.3. KEY CHALLENGES
    • 6.1.4. KEY PLAYERS
    • 6.1.5. COUNTRY ANALYSIS
      • 6.1.5.1. UNITED STATES
      • 6.1.5.2. CANADA
  • 6.2. EUROPE
    • 6.2.1. MARKET SIZE & ESTIMATES
    • 6.2.2. KEY GROWTH ENABLERS
    • 6.2.3. KEY CHALLENGES
    • 6.2.4. KEY PLAYERS
    • 6.2.5. COUNTRY ANALYSIS
      • 6.2.5.1. UNITED KINGDOM
      • 6.2.5.2. GERMANY
      • 6.2.5.3. FRANCE
      • 6.2.5.4. ITALY
      • 6.2.5.5. BELGIUM
      • 6.2.5.6. POLAND
      • 6.2.5.7. REST OF EUROPE
  • 6.3. ASIA-PACIFIC
    • 6.3.1. MARKET SIZE & ESTIMATES
    • 6.3.2. KEY GROWTH ENABLERS
    • 6.3.3. KEY CHALLENGES
    • 6.3.4. KEY PLAYERS
    • 6.3.5. COUNTRY ANALYSIS
      • 6.3.5.1. CHINA
      • 6.3.5.2. JAPAN
      • 6.3.5.3. INDIA
      • 6.3.5.4. SOUTH KOREA
      • 6.3.5.5. INDONESIA
      • 6.3.5.6. THAILAND
      • 6.3.5.7. VIETNAM
      • 6.3.5.8. AUSTRALIA & NEW ZEALAND
      • 6.3.5.9. REST OF ASIA-PACIFIC
  • 6.4. REST OF WORLD
    • 6.4.1. MARKET SIZE & ESTIMATES
    • 6.4.2. KEY GROWTH ENABLERS
    • 6.4.3. KEY CHALLENGES
    • 6.4.4. KEY PLAYERS
    • 6.4.5. REGIONAL ANALYSIS
      • 6.4.5.1. LATIN AMERICA
      • 6.4.5.2. MIDDLE EAST & AFRICA

7. COMPETITIVE LANDSCAPE

  • 7.1. KEY STRATEGIC DEVELOPMENTS
    • 7.1.1. MERGERS & ACQUISITIONS
    • 7.1.2. PRODUCT LAUNCHES & DEVELOPMENTS
    • 7.1.3. PARTNERSHIPS & AGREEMENTS
    • 7.1.4. BUSINESS EXPANSIONS, ANNOUNCEMENTS, & DIVESTITURES
  • 7.2. COMPANY PROFILES
    • 7.2.1. ALLERGAN PLC (ACQUIRED BY ABBVIE)
    • 7.2.2. AMARANTUS BIOSCIENCE HOLDINGS INC
    • 7.2.3. BAXTER INTERNATIONAL INC
    • 7.2.4. BIOGEN INC
    • 7.2.5. COGNOPTIX INC
    • 7.2.6. EISAI CO LTD
    • 7.2.7. ELI LILLY & COMPANY
    • 7.2.8. F HOFFMANN-LA ROCHE
    • 7.2.9. GE HEALTHCARE
    • 7.2.10. JOHNSON & JOHNSON
    • 7.2.11. LUPIN LIMITED
    • 7.2.12. MERCK & CO INC
    • 7.2.13. NOVARTIS AG
    • 7.2.14. PFIZER INC
    • 7.2.15. SIEMENS HEALTHINEERS AG
    • 7.2.16. SUN PHARMACEUTICALS INDUSTRIES LTD
    • 7.2.17. TEVA PHARMACEUTICAL INDUSTRIES LIMITED
    • 7.2.18. ZYDUS CADILA
Back to Top
전화 문의
F A Q